Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer's Disease Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patients must have probable Alzheimer's disease of mild or moderate severity.
A brain scan and laboratory results must be consistent with Alzheimer's disease.
The patient must be otherwise medically healthy.

Treatment and study plan

MK0677

Drug

Primary outcomes

Cognitive function over 12 month period; safety and tolerability

Time frame: over 12 month period

Secondary outcomes

AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.

Time frame: over a 6 month and 12 month period

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

Important dates

Study start: 2003
Primary completion: 2006
Study completion: 2006
First posted: Dec 16, 2003
Registry last updated: Jul 24, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed